Bronchopulmonary dysplasia is an important complication of ventilation in babies for which treatment with steroids has been advocated. We report the results of a phase I study of early i.v. dexamethasone to prevent the development of bronchopulmonary dysplasia in a high-risk population of ventilated premature babies, < 30 wk gestation, with surfactant-treated respiratory distress syndrome. This study used a limited dexamethasone dosing regimen to minimize toxicity but used administration early in the course of acute lung disease to interrupt the injury cycle. Forty babies were enrolled; 19 were randomized to receive dexamethasone (0.5 mglkg birth weight at 12-18 h of age and a second dose 12 h later) and 21 were randomized to receive placebo (i.v. saline). The dexamethasone group required less ventilatory support (mean airway, peak inspiratory and end expiratory pressures, and intermittent mandatory ventilation) and supplemental oxygen after methasone group was 89% versus 67% in the placebo group @ = 0.08, XZ analysis). Survival without bronchopulmonary dysplasia, diagnosed at 36 wk corrected gestational age, was 68% in the dexamethasone group versus 43% in the placebo group @ = 0.14). Mean blood pressure was elevated on study d 4 through 7 in the dexamethasone group, but this difference resolved by study d 10 without pharmacologic intervention. No differences in hyperglycemia, incidence of intraventricular hemorrhage (or its severity), or days to regain birth weight were seen. Early administration of dexamethasone resulted in short-term and suggested long-term benefits without significant complications. The results of this trial justify a large scale, broaderbased (phase 11) trial in premature babies with respiratory distress syndrome to determine the limits of effectiveness and the incidence of less-frequent potential side effects. 
methasone group was 89% versus 67% in the placebo group @ = 0.08, XZ analysis). Survival without bronchopulmonary dysplasia, diagnosed at 36 wk corrected gestational age, was 68% in the dexamethasone group versus 43% in the placebo group @ = 0.14). Mean blood pressure was elevated on study d 4 through 7 in the dexamethasone group, but this difference resolved by study d 10 without pharmacologic intervention. No differences in hyperglycemia, incidence of intraventricular hemorrhage (or its severity), or days to regain birth weight were seen. Early administration of dexamethasone resulted in short-term and suggested long-term benefits without significant complications. The results of this trial justify a large scale, broaderbased (phase 11) trial in premature babies with respiratory distress syndrome to determine the limits of effectiveness and the incidence of less-frequent potential side effects. (Pediatr Res 36: 122-128, 1994) Abbreviations BPD, bronchopulmonary dysplasia FiO,, fraction of inspired oxygen concentration MAP, mean airway pressure RDS, respiratory distress syndrome CGA, corrected gestational age requiring home medical care and frequent outpatient visits (1-5). The incidence of BPD has an inverse relationship with birth weight and gestational age (6). With the development and application of exogenous surfactant replacement therapy for the treatment of RDS as well as other advances in neonatal care, survival of low birth weight, extremely premature babies is increasing. The greatest risk for the development of BPD accompanies the improved survival in this group of babies.
Steroids have been used in a number of controlled trials to treat established BPD and have demonstrated significant short-term improvements in lung function (7-9). Postulated mechanisms by which steroids might improve lung function include the stabilization of cell and lysosomal membranes, increase in surfactant synthesis, inhibition of prostaglandin and leukotriene synthesis, decrease in neutrophil recruitment to the lung, enhancement of (3-adrenergic activity, and reduction of pulmonary edema (10). A controlled trial of steroids in ventilated premature babies, administered at 2 wk of age, resulted in improved pulmonary and neurodevelopmental outcomes (1 1). Although these babies were treated early, before developing BPD by classic definitions (i.e. 28 d of age with an oxygen requirement and characteristic chest x-ray changes), this study did not address prophylactic steroids to prevent the development of BPD. Evidence suggests that the pathophysiology of BPD may begin shortly after birth in susceptible babies (12). One controlled trial has investigated the use of prophylactic steroids in babies with RDS before the development of BPD (13). In that study, early (< 12 h) i.v. dexamethasone was given to premature babies with RDS, and the course was tapered over a 12-d period (13). Infants were a mean of 30 wk gestation and surfactant was not used. The results showed improved pulmonary function, earlier extubation, and a decreased incidence of lung injury in the treatment group; however, this group also demonstrated increased blood pressure, increased plasma glucose concentrations, and delayed somatic growth (13). This raised concerns over the safety of using steroids in a very-lowbirth-weight population.
The potential for serious sequelae from the use of steroids in premature babies remains a concern. At the same time, we also wished to learn whether a benefit could accrue to younger, surfactant-treated infants. Therefore, we conducted a study to estimate the efficacy and safety of a short course of dexamethasone to ventilator-dependent premature babies with surfactant-treated RDS. We limited the duration of dexamethasone administration to two doses to reduce the potential risk for significant sequelae and to test our hypothesis that the onset of BPD is based on an early inflammatory lung injury.
METHODS
This study was performed at the University of Rochester Medical and Strong Children's Research Centers, Rochester, New York, from December 1989 through January 1991. The study was approved by the Research Subjects Review Board of the University and informed consent was obtained from the babies' parents.
Patient population. Babies of less than 30 wk gestation were eligible if they had RDS diagnosed by clinical and radiographic signs, required mechanical ventilation at 12-18 h of age, and had received at least one dose of exogenous surfactant. During the enrollment period of the study, all babies born at the University of Rochester of less than 29 wk gestation received the first dose of exogenous surfactant in the delivery room prophylactically based on our demonstration of its superiority over rescue therapy in this population (14) . Babies of 29-30 wk gestation, inclusive, who were born outside of or at the University of Rochester received exogenous surfactant if they met specific criteria after admission. The purpose for requiring exogenous surfactant replacement therapy for study eligibility was to maintain as uniform a study population as possible. All infants were eligible to receive subsequent doses of exogenous surfactant if they continued to require mechanical ventilation with an MAP 1 7 torr, an FiOz r 0.4, or both. Exclusion criteria at entry included a strong suspicion of sepsis or pneumonia (i.e. chest x-ray findings not consistent with RDS, cardiovascular instability, neutropenia, severe maternal chorioamnionitis), congenital heart disease, chromosomal abnormalities, and those infants who received an exchange transfusion.
Randomization. After identification of eligible babies and informed consent, an order form was sent to the pharmacy. There babies were randomized to the dexamethasone or placebo group according to a set of sealed envelopes. A syringe labeled "dexamethasone study drug," containing either the appropriate dose of dexamethasone or normal saline placebo according to the randomization schedule, was then sent to the nursery. A second syringe identical with the first was sent to the nursery 12 h later.
Intervention. The treatment group received one dose of i.v. dexamethasone (0.5 mglkg birth weight) between 12 and 18 h of age and a second dose 12 h later. The placebo group received an equal volume of i.v. normal saline using the same dosing schedule. Investigators and caretakers were blinded to the study drug. All other aspects of care were according to the standard practice of the neonatal intensive care unit at the Strong Children's Medical Center.
Short-term clinical outcome variables and pulmonary function testing. Short-term clinical outcome variables were obtained on d 1 through 7 and d 10 of age and included weight, mean blood pressure, peak blood glucose, complete blood counts with differential, need for insulin or antihypertensive therapies, need for pharmacologic blood pressure support, and degree of ventilatory support. The latter included results of blood gas analysis (pH and blood gas tension values) and ventilator settings: peak inspiratory pressure, peak end-expiratory pressure, MAP, intermittent mandatory ventilation, and FiO,. Pulmonary function testing was scheduled for d 7 for those infants who remained ventilated, and determinations of minute ventilation, tidal volume, compliance, and resistance were made (15). During pulmonary function testing, infants were placed on endotracheal tube continuous positive airway pressure and only spontaneous breaths were analyzed.
Long-term clinical outcome variables. Long-term clinical outcome variables included survival, disposition (i.e. discharged to home, transferred to another hospital, died), age at extubation, days on the ventilator, days requiring supplemental oxygen, days to regain birth weight, presence and severity of intraventricular hemorrhage, need for home oxygen and medications (i.e. diuretics, bronchodilators, methylxanthines), total number of hospital days (this includes hospital days at other institutions for infants transferred before discharge home), and survival without BPD. BPD was defined as the need for supplemental oxygen and characteristic chest x-ray changes at 36 wk CGA (16). All x-rays were read in a blinded fashion by a single pediatric radiologist.
Statistical analysis. Continuous variables were analyzed using t tests and analysis of covariance with adjustment for birth weight. Measurements recorded at a number of different time points were analyzed by repeated measures analysis of variance with the Greenhouse-Geisser correction for degrees of freedom. Discrete variables were analyzed using Mann-Whitney tests and X 2 tests. Survival type endpoints, such as days in the hospital, were analyzed using the Kaplan-Meier estimate of the survival function. Proportional hazards regression analysis was used to adjust for birth weight. For endpoints such as days in the hospital, babies who died were treated as never discharged, i.e. infants who died were assigned a value equal to the longest observation time in the study. Thus, when the Kaplan-Meier curves are computed, such infants remain in the risk set for the entire analysis. In practical terms, then, such babies are treated as not reaching endpoint (discharged or extubated) for the entire time interval under analysis. This was done to avoid biasing the survival analysis by having babies who died removed from the analysis. All p values are two-sided.
RESULTS
Patient population. During the study period, 113 babies of less than 30 wk gestation were admitted to the University of Rochester neonatal intensive care unit. Of these 113,28 did not meet entry criteria, eight died before enrollment, 24 were excluded due to presumed sepsis, two were not enrolled because of refused parental consent, one was deemed too critically ill by the neonatal attending physician, and 10 missed enrollment. Forty babies were enrolled during the study period, with 21 randomized to the placebo group and 19 randomized to the dexamethasone group. No differences were seen between the two groups with respect to birth weight, estimated gestational age, gender, race, 1-and 5-min Apgar scores, initial white blood cell count, the number receiving prophylactic surfactant, or antepartum factors (Table 1) . Table 2 summarizes clinical and laboratory characteristics immediately before treatment intervention. No clinically significant differences were seen between the two groups with respect to degree of ventilatory support, blood gas results, serum glucose, or mean blood pressure.
Pulmonaryfinction. The goal of the ventilatory strategy used was to maintain the arterial Po, between 6.7 and 9.3 kPa (50 and 70 mm Hg) and the arterial Pco, between 6.0 and 7.3 kPa (45 and 55 mm Hg). Figure 1 displays the MAP and FiO, (panels A and B, respectively) over time in the dexamethasone and placebo groups. These data were analyzed using two-way repeated measures analysis of variance. This analysis includes a test of interaction whose null hypothesis states that the two curves are parallel over time. A significant result indicates that the two curves are not parallel and therefore that differences between the two groups change over time (and in particular are not all zero). The nature of these differences can be seen in Figure 1 . Infants in the dexamethasone group required less MAP after study d 3; p = 0.003 for the test of interaction indicated a significant change in the difference between the two groups over time (Fig. M) , with the largest differences occurring after d 3. Similar statistically significant findings were also seen for peak inspiratory pressure, peak end-expiratory pressure, and intermittent mandatory ventilation (data not shown). In addition to decreased ventilatory support, infants in the dexamethasone group required less supplemental oxygen after study d 4, with the greatest differences on study d 6 and 7 @ = 0.04, test of interaction) (Fig. 1B) . Blood gas analyses revealed no significant differences between the two groups during the same period (data not shown). Pulmonary function testing, including measurements of tidal volume, minute ventilation, compliance, and resistance, was performed on study d 7. Tidal volumes were significantly higher in babies receiving dexamethasone @ = 0.02, t test) (Table 3 ). This examination was obviously limited by extubation of the healthier infants before pulmonary function testing could be performed. However, there was no significant difference between the two groups with respect to the percentage of infants extubated and alive at d 7.
Long-term outcome. Survival in the dexamethasone group was 17 of 19 (89%) versus 14 of 21 (67%) in the placebo group @ = 0.08, X 2 analysis) ( Table 3) . Survival analysis using proportional hazards regression with adjustment for birth weight produced similar results. Table  4 lists the primary and secondary diagnoses and the age at death for the nonsurvivors from both groups. One infant in the dexamethasone group and one infant in the placebo group died during the first week postpartum. Infants in the dexamethasone group required fewer days of mechanical ventilation and fewer days in the hospital (Table  3 ). The Kaplan-Meier curves for percentage of patients extubated and discharged home versus age in days are shown in Figure 2 . The cumulative rates of extubation seem to be very similar until about 40 d, when the rate of extubation rises dramatically in the dexamethasonetreated group, exceeding 90% by 50 d. In contrast, the cumulative rate for extubation in the placebo group does not exceed 70% by 120 d. Similarly, the cumulative rates for the percentage of patients discharged in both groups are approximately equivalent until 90 d, at which point the groups diverge. The cumulative rate in the dexamethasone group approaches 90%, whereas in the placebo group it does not exceed 70% by 120 d. Survival without BPD, diagnosed at 36 wk CGA, was 68% in the dexamethasone group compared with 43% in the placebo group (p = 0.14, X 2 analysis) (Table 3) (95% confidence interval for difference between the treatment groups was -4.2% to 55.3%). One baby in the dexamethasone group who survived without BPD received late steroids (i.e. after d 2 of age). Survival without BPD and without late steroids was 63% (12 of 19) in the dexamethasone group and 43% (nine of 21) in the placebo group (p = 0.16, X 2 analysis) (Table 3 ) (95% confidence interval for this difference was -10.0% to 50.6%). Among the four surviving infants in the dexamethasone group with BPD, two were treated with late steroids. In the 14 placebo survivors, nine were free of BPD at 36 wk CGA, and none of these infants were treated with late steroids. Among the five surviving placebo infants with BPD, one was treated with late steroids. For the three placebo-treated infants who died after 36 wk CGA, all had BPD and two were treated with late steroids.
Complications. No significant differences between the two groups were seen with respect to the incidence or severity of intraventricular hemorrhage, the need for insulin therapy, the need for antihypertensive therapies, the number of positive admission blood cultures, or the number of days to regain birth weight (Table 5) . No clinically significant differences were noted in the mean daily blood glucose values, although values were greater in the dexamethasone group (Fig. 3A) . Mean blood pressure was elevated on study d 4 through 7 in the dexamethasone group (Fig. 3B) . This difference, however, resolved by study d 10 without pharmacologic intervention. No significant differences between the two groups were seen with respect to necrotizing enterocolitis, retinopathy of prematurity, air leak (i.e. pneumothorax or pulmonary interstitial emphysema), or the need for home oxygen or medications (Table 5) .
DISCUSSION
The incidence of BPD is increasing because of the improved survival of critically ill premature and term babies (12, 17) . BPD is a leading cause of neonatal mortality and morbidity during the first year of life. Lowering the incidence and severity of BPD would offer significant benefit to this high-risk group of babies. By decreasing the need for assisted ventilation and supplemental oxygen in the early stages of the disease process and alleviating the need for further pharmacologic interventions, the potential for adverse sequelae would be substantially reduced.
The exact pathogenesis of BPD remains unclear. One hypothesis for the development of BPD is that hyperoxic injury and barotrauma from mechanical ventilation cause lung cell membrane damage and the release of potent inflammatory mediators (18). This inflammatory response, with an influx of neutrophils, generates oxygen radicals and the release of proteolytic enzymes. This process evolves into chronic lung disease, with varying degrees of fibrosis, because of a cascade of events including cytokine release and enzymatic damage (18). The premature infant is at greater potential risk for hyperoxiainduced injury because of a relatively deficient pulmonary antioxidant enzyme system (19, 20) . Similar to the surfactant system, the pulmonary antioxidant enzyme system matures rapidly late in gestation and may represent a necessary preparatory event for the transition to a relatively hyperoxic environment after birth (20, 21) .
Animal studies have demonstrated that the pattern of pulmonary antioxidant enzyme maturation can be accelerated by the administration of steroids (22, 23). Additionally, the administration of dexamethasone in term neonatal piglets decreased the extent of lung injury caused by hyperoxia and mechanical ventilation as determined both histologically and by analysis of bronchoalveolar lavage (24, 25) . The early administration of dexamethasone may reduce the early inflammatory response that normally occurs in the pathogenesis of BPD.
For this initial study, we chose the population at highest risk for development of BPD (6). The role of prophylactic dexamethasone intervention in this population, in an era of exogenous surfactant replacement therapy, has not been previously studied. Yeh et al. (13) demonstrated improved tidal volume, minute ventilation, and lower MAP requirement during the first week of life in babies with non-surfactant-treated RDS who received early dexamethasone, tapered over the first 12 d of age. We demonstrated similar short-term results (i.e. lower MAP and FiO,, improved tidal volume) with only two doses of dexamethasone in a surfactant-treated population of babies with RDS who were of an earlier gestational age (26-27 wk versus 30 wk in the Yeh study). Differences in tracheal aspirate elastase and a,-proteinase inhibitor activities as well as other markers of inflammation (i.e. cell count, differential) have been demonstrated in the first week of age between babies with RDS who develop BPD and those who do not (26). Early dexamethasone may function by interrupting the cytokine cascade that generates this early inflammatory response in those babies who ultimately develop BPD. Tumor necrosis factor-a is a potent mediator of pulmonary inflammation and was shown to increase after d 3 of age in premature babies with RDS (27). Levels of tumor necrosis factor-a were higher in the group requiring prolonged oxygen treatment beyond 28 d of age and were reduced in six babies by dexamethasone treatment (27). In vitro studies have shown that the expression of IL-8, a potent neutrophilactivating and chemotactic peptide produced by mononuclear phagocytes, was inhibited by pretreatment with dexamethasone in stimulated alveolar macrophages (28). The treatment with dexamethasone after stimulation, however, failed to inhibit IL-8 expression (28). This suggests that a temporal limitation may exist beyond which the alveolar macrophage is not affected by dexamethasone administration.
If early dexamethasone interrupts the cascade of events that results in an inflammatory response and ultimately BPD in babies with RDS, one would predict that such an intervention would affect both survival and the incidence of BPD. Yeh et al. (13) demonstrated a decrease in the
